Euglycemic Diabetic Ketoacidosis Following Treatment with Tirzepatide and SGLT-2 Inhibitors: A Case Report and Literature Review.
Toshitaka Sawamura, Shigehiro Karashima, Ai Ohmori et al.
✦ AI-curated · Sources linked
Case in brief
A patient receiving tirzepatide and an SGLT-2 inhibitor developed euglycemic diabetic ketoacidosis while continuing both medications during a sick-day condition. The report highlights appetite loss as a relevant concern with tirzepatide and the potential for EDKA in the setting of SGLT-2 inhibitor use. After the sick-day condition resolved, both agents were reintroduced successfully, with no adverse effects reported.
What made this case unusual
EDKA occurred while the patient continued both tirzepatide and an SGLT-2 inhibitor during a sick-day condition; both medications were later reintroduced without reported adverse effects.
Diagnostic / clinical pearl
During sick-day conditions, consider EDKA in patients taking SGLT-2 inhibitors, particularly when appetite loss accompanies continued tirzepatide use.